Cite
HARVARD Citation
Vallespi, M. et al. (2021). A first‐in‐class, first‐in‐human, phase I trial of CIGB‐552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF‐κB in patients with advanced solid tumors. International journal of cancer. 149 (6), pp. 1313-1321. [Online].